ClinicalTrials.gg
RecruitingNCT07172256Updated Jul 30, 2026

CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs

A Phase 2 interventional study of CUE-101 and Pembrolizumab in Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma and New Diagnosis Tumor, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Yale University · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States — 213 open to participants now, 347 under way, 28 of them phase 3. Squamous Cell Carcinoma of Head and Neck · United States.

Planned enrollment
591st of 994
30 · median 41
Started
2026
with 59 others
Phase 2
359 of 1,099
58 open now
Primary completion
2031-02
later than 321 of 346 live
Registered
1,037th of 1,099
by date

Among the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, this one is the 591st largest by planned enrollment of the 994 interventional ones that give a count, is one of 60 that started in 2026, is one of 359 in phase 2, reaches primary completion later than 321 of the 346 other live ones, and was the 1,037th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

213 of the 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States are open now. Recruiting first, the newest first:

208 more — sign in →

All 213 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Squamous Cell Carcinoma of Head and Neck with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A*0201-positive treatment naive participants with locally advanced HPV-16 associated head and neck squamous cell carcinoma (HNSCC).

Read the detailed description

This is a phase 2, pilot, randomized, open-label 3-arm study to assess the safety, tolerability, and efficacy of CUE-101 monotherapy, and CUE-101 in combination with pembrolizumab as neoadjuvant therapy in HLA-A*0201-positive treatment naive participants with locally advanced HPV-16 associated head and neck squamous cell carcinoma (HNSCC).

CUE-101 monotherapy will be administered at 4 mg/kg IV on Days 1 and 21. Pembrolizumab monotherapy will be administered at 200 mg IV on Days 1 and 21. CUE-101 and pembrolizumab combination therapy will be administered by sequential infusion. Pembrolizumab will be administered at 200 mg IV followed by CUE-101 will be administered at 4 mg/kg IV on Days 1 and 21.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
  • HPV Positive Oropharyngeal Squamous Cell Carcinoma
  • New Diagnosis Tumor
  • Locally Advanced
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have or cytologically confirmed new diagnosis of locally advanced, non-, head and neck squamous cell carcinoma of the oropharynx (cT1-4 N0-N3 M0)
  • Participants must be deemed unresectable by a head and neck surgeon for one or more of the following reasons:

    1. Inability to obtain a R0 resection with a minimally invasive surgical approach, such as Transoral Robotic Surgery (TORS)
    2. Risk of significant functional deficit with a surgical treatment approach
    3. Other anatomical (such as retropharyngeal location of the carotid artery) or tumor characteristics that in the surgeon's judgment would be a to a minimally invasive surgical approach.
  • Participants with newly diagnosed HNSCC who underwent partial surgical resection and have gross residual disease are eligible for the study if additional treatment is required.
  • Participant must have a tumor that is HPV-16 positive and express p16INK4A. or formalin fixed, paraffin-embedded (FFPE) tissue from a biopsy and/or surgery must be available for HPV-16 and p16INK4A testing on all participants enrolled. All tumors must test positive for HPV-16 using ISH analysis or using HPV16 specific PCR testing and p16INK4A expression in tumor cells using IHC analysis.
  • Archival tissue or formalin fixed, paraffin-embedded (FFPE) tissue from a biopsy and/or surgery must be available for staining. Tumors must be scored for CPS.
  • Participants must have HLA-A*0201 genotype as determined by genomic testing.
  • Participants must have , defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm (≥2 cm) by chest x-ray or as ≥10 mm (≥1 cm) for non-nodal lesions and > 15mm (>1.5 cm) for nodal lesions with CT scan, magnetic resonance imaging (MRI), or calipers by clinical exam. See section 11 (Measurement of Effect) for the evaluation of measurable disease.
  • Age ≥18 years. Since no dosing or adverse event data are currently available on the use of CUE-101 alone or in combination with pembrolizumab in participants \<18 years of age, children are excluded from this study.
  • performance status of 0 or 1 ( ≥60%, see Appendix A).
  • Participants must have adequate organ and marrow function as defined below in the protocol
  • (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • For participants with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Participants with a history of virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Participants with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.
  • Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, participants should be class 2B or better.
  • A male participant must agree to use of a highly effective method of during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of (WOCBP) as defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or is not or
    2. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 120 days after the last dose of study treatment.
    3. Highly effective methods of contraception:

    i. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal.

ii. Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable.

iii. Non-hormonal (copper) intrauterine device. iv. Intrauterine hormone-releasing system. v. Bilateral tubal occlusion/ligation. vi. Sexual abstinence, i.e., refraining from heterosexual intercourse (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant).

vii. Vasectomized sexual partner (provided that partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has received medical assessment of the surgical success).

  • Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Has distant or radiographically detectable (even if asymptomatic and/or previously treated) central nervous system metastases and/or carcinomatous meningitis as assessed by local site investigator and radiology review.
  • A who has a positive urine pregnancy test within 72 hours prior to first dose of study drug. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
  • Participants who received prior radiotherapy treatment or systemic anticancer therapy including any other agents for the HNC under study prior to first dose of study drug.
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study drug.
  • History of allergic reactions attributed to compounds of similar chemical or biologic. composition to recombinant proteins, polysorbate 80 or any contained in the drug formulation for CUE-101 or pembrolizumab.
  • Participants with any history of known or suspected disease with the specific exceptions of the following:

    1. Vitiligo.
    2. Resolved childhood atopic dermatitis.
    3. Psoriasis (with exception of psoriatic arthritis) not requiring systemic treatment (within the past 2 years).
    4. Participants with a history of Grave's disease that are now euthyroid clinically and by laboratory testing.
    5. Hashimoto's thyroiditis.
  • History of prior allogeneic bone marrow, stem-cell or solid organ transplantation.
  • Treatment with (>10 mg per day prednisone or equivalent) or other immune suppressive drugs within the 7 days prior to the first dose of study drug administration. Steroids for topical, ophthalmic, inhaled, or nasal administration are allowed. Physiological replacement with hydrocortisone up to a maximum dose of 10 mg per day is allowed.
  • History of cardiovascular disease including:

    1. Myocardial infarction or unstable angina within the 16 weeks prior to the initiation of study drug.
    2. Clinically significant cardiac arrhythmias.
    3. Uncontrolled hypertension: systolic blood pressure (BP) > 180 mmHg, diastolic BP >100 mmHg.
    4. Deep vein thrombosis, pulmonary embolism, stroke, or within the 16 weeks prior to the initiation of study drug.
    5. prolongation > 480 msec.
    6. Congestive heart failure ( class III-IV).
    7. Pericarditis/clinically significant pericardial effusion.
    8. Myocarditis.
  • Clinically significant pulmonary compromise (e.g., requirement for supplemental oxygen)
  • Clinically significant GI disorders including:

    1. History of GI perforation within 1 year prior to study drug administration. Participants with a history of GI perforation that occurred more than 1 year ago can only be enrolled if the sponsor-investigator no longer considers the previously affected area to be at risk for perforation.
    2. History of clinically significant GI bleeding within 3 months prior to the initiation of study drug.
    3. History of acute pancreatitis within 3 months prior to the initiation of study drug.
    4. Diverticulitis that is clinically significant in the opinion of the sponsor-investigator based on the extent or severity of known disease and/or the occurrence of clinically significant disease flares within four weeks prior to the initiation of study drug administration.
  • Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within seven days prior to the initiation of study drug. Participants requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than 1 week prior to the initiation of study drug
  • Second primary invasive that has not been in remission for > 2 years. Exceptions that do not require a 2-year remission include: non-melanoma skin cancer; cervical carcinoma in situ on ; or squamous intraepithelial lesion on Pap smear; localized prostate cancer (Gleason score \<6); or resected melanoma in situ.
  • History of trauma or major surgery within 4 weeks prior to first dose of study drug.
  • Has received a within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist) are live attenuated vaccines and are not allowed.
  • Has Grade > 2 audiometric hearing loss. Note: Audiometric abnormalities without corresponding clinical symptoms of Grade > 2 hearing loss will not be grounds for exclusion.
  • Has Grade > 2 neuropathy.
  • Has Grade > 2 bleeding due to the underlying malignancy.
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
  • Active or history of alcohol or other substance abuse within 1 year prior to the initiation of study drug administration.
  • Participants with uncontrolled intercurrent illness.
  • Participants with psychiatric illness/social situations that would limit compliance with study requirements, as determined by the treating investigator.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  • Any investigative site personnel directly affiliated with this study.
  • Prisoners or other individuals who are involuntarily detained.
  • Pregnant women are excluded from this study because it is unknown whether CUE-101 and/or pembrolizumab is an agent with the potential for teratogenic or abortifacient effects. It is unknown whether pembrolizumab is excreted in human milk. Since many drugs are excreted in human milk, and because of the potential for serious adverse reactions in the nursing infant, participants who are breast feeding are not eligible for enrollment.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant CUE-101

    Neoadjuvant therapy followed by definitive surgical resection

    Drug: CUE-101

  • Experimental
    Neoadjuvant Pembro

    Pembrolizumab Neoadjuvant therapy followed by definitive surgical resection

    Drug: Pembrolizumab

  • Experimental
    Neoadjuvant CUE-101 + Pembro

    CUE-101+Pembrolizumab as neoadjuvant therapy followed by definitive surgical resection

    Drug: CUE-101 · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Measurement of HPV-16 E711-20-Specific CD8+ T Cells in Peripheral Blood

    This outcome measure evaluates the immune response by quantifying the presence of HPV-16 E711-20-specific CD8+ T cells in the peripheral blood at the conclusion of neoadjuvant treatment. The assessment will involve collecting blood samples from participants and analyzing them for the presence and quantity of these specific CD8+ T cells using immunological assays. The primary endpoint is the change in the number of HPV-16 E711-20-specific CD8+ T cells from baseline to the end of the treatment period.

    Time frame: Baseline and perioperative/periprocedural

Secondary outcomes

  1. Assessment of Safety and Tolerability of CUE-101 Alone and in Combination with Pembrolizumab

    This secondary outcome measure evaluates the safety and tolerability of CUE-101, both as a monotherapy and in combination with pembrolizumab, in the neoadjuvant setting. Safety assessments will include monitoring and recording adverse events, serious adverse events, and any dose-limiting toxicities according to the Common Terminology Criteria for Adverse Events (CTCAE) guidelines. Additionally, tolerability will be assessed through patient-reported outcomes and clinical observations. The study will record and analyze the frequency, severity, and relationship of adverse events to the study treatments over the course of the treatment period. The secondary endpoint is to determine the incidence, nature, and duration of adverse events, and to provide an overall tolerability profile of the therapeutic regimens.

    Time frame: Up to 30 days

  2. Evaluation of Pathological Response Rate at End of Neoadjuvant Treatment

    This secondary outcome measure aims to evaluate the rate of pathological response in participants who undergo subsequent resection after completing neoadjuvant treatment. Pathological response will be assessed by examining resected tumor samples post-treatment to determine the extent of cancer cell death and tumor regression. The assessment criteria will include standardized histopathological evaluation methods to classify the degree of response, ranging from complete pathological response (no residual tumor) to partial or minimal response. The secondary endpoint is the proportion of participants achieving each defined level of pathological response at the time of surgery, providing insight into the effectiveness of the neoadjuvant treatment in inducing tumor regression.

    Time frame: At screening and on the day of surgery

  3. Evaluation of Radiologic Response Rate at End of Neoadjuvant Treatment

    This secondary outcome measure aims to evaluate the radiologic response rate among participants at the conclusion of neoadjuvant treatment. Radiologic response will be assessed using imaging studies, CT/MRI head and neck, chest and upper abdomen, conducted before and after the treatment period. The response will be evaluated according to standardized criteria, such as the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines, to classify the degree of tumor size reduction and overall response to treatment. The secondary endpoint is the proportion of participants achieving each defined level of radiologic response (complete response, partial response, stable disease, or progressive disease) at the end of the neoadjuvant treatment period. This evaluation will provide important insights into the effectiveness of the neoadjuvant therapy in reducing tumor burden as evidenced by imaging studies.

    Time frame: Baseline and perioperative/periprocedural

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2031, 57 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 57 months is close to that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 15, 2025
StartActual
May 7, 2026
Primary completionEst.
Feb 2031
CompletionEst.
Feb 2031
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07172256
Lead sponsor
Yale University
Collaborators
Cue Biopharma, National Cancer Institute (NCI)
Responsible party
Sara Pai (Professor, Yale University) — Principal investigator
First posted
Sep 15, 2025
Start date
May 7, 2026
Primary completion
Feb 2031 (estimated)
Completion
Feb 2031 (estimated)
Last update
Jul 30, 2026

Study contacts

Sara Pai
Contact
sara.pai@yale.edu
(203) 836-0406
Sara Pai, MD
principal investigator · Yale University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HPV16 E7-specific HLA-A*02:01-restricted IgG1-Fc Fusion Protein CUE-101

Start the discussion